Exelixis' Cometriq rebounds with NSCLC data
This article was originally published in Scrip
Exelixis's anticancer Cometriq has redeemed itself slightly following its major setback in the Phase III COMET-1 trial in prostate cancer with some promising Phase II data in non-small cell lung cancer, another major potential indication. Shares in the company were up by us much as 15% on the announcement to peak at $1.92 on 5 November on Nasdaq.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.